KRAS and colorectal carcinoma: This study also performed in vivo testing of MCI-062 on a syngeneic mouse model of KRAS-driven CRC (CT-26) and demonstrated that MCI-062 acted on its target, reduced GTP-RAS, suppressed the activation of the MAPK signaling pathway, and inhibited tumor growth.